NCT05277051 - First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

September 12, 2028

Study Completion Date

September 12, 2028

Conditions

Neoplasms

Interventions

DRUG

GSK4381562

GSK4381562 will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered.

DRUG

Belrestotug

Belrestotug will be administered.

DRUG

Nelistotug

Nelistotug will be administered.

DRUG

GSK5764227

GSK5764227 will be administered.

Trial Locations (24)

6009

RECRUITING

GSK Investigational Site, Nedlands

19111

RECRUITING

GSK Investigational Site, Philadelphia

21000

RECRUITING

GSK Investigational Site, Dijon

28040

RECRUITING

GSK Investigational Site, Madrid

28050

RECRUITING

GSK Investigational Site, Madrid

28204

RECRUITING

GSK Investigational Site, Charlotte

29010

RECRUITING

GSK Investigational Site, Málaga

59000

RECRUITING

GSK Investigational Site, Lille

73104

RECRUITING

GSK Investigational Site, Oklahoma City

75230

RECRUITING

GSK Investigational Site, Dallas

78229

RECRUITING

GSK Investigational Site, San Antonio

84112

RECRUITING

GSK Investigational Site, Salt Lake City

94158

RECRUITING

GSK Investigational Site, San Francisco

200126

RECRUITING

GSK Investigational Site, Shanghai

250117

RECRUITING

GSK Investigational Site, Jinan

K1H 8L6

RECRUITING

GSK Investigational Site, Ottawa

M5G 2M9

RECRUITING

GSK Investigational Site, Toronto

277-8577

RECRUITING

GSK Investigational Site, Chiba

104-0045

RECRUITING

GSK Investigational Site, Tokyo

03080

RECRUITING

GSK Investigational Site, Seoul

03722

RECRUITING

GSK Investigational Site, Seoul

08035

RECRUITING

GSK Investigational Site, Barcelona

M20 4BX

RECRUITING

GSK Investigational Site, Manchester

SM2 5PT

RECRUITING

GSK Investigational Site, Sutton